Bavarian Nordic A/S (BAVA.CO)
DKK 198.95
(2.82%)
DKK 198.95
(2.82%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.47 Billion DKK | 524.66% |
| 2022 | -347.38 Million DKK | 25.26% |
| 2021 | -464.77 Million DKK | -267.47% |
| 2020 | 277.52 Million DKK | 180.03% |
| 2019 | -346.77 Million DKK | 4.19% |
| 2018 | -361.92 Million DKK | -299.58% |
| 2017 | 181.34 Million DKK | 492.62% |
| 2016 | 30.6 Million DKK | -48.51% |
| 2015 | 59.42 Million DKK | 129.09% |
| 2014 | 25.94 Million DKK | 155.51% |
| 2013 | -46.72 Million DKK | 80.53% |
| 2012 | -240 Million DKK | 26.0% |
| 2011 | -324.33 Million DKK | 43.79% |
| 2010 | -576.96 Million DKK | -45.7% |
| 2009 | -395.98 Million DKK | -83.12% |
| 2008 | -216.24 Million DKK | -240.52% |
| 2007 | -63.5 Million DKK | 60.54% |
| 2006 | -160.93 Million DKK | -69.89% |
| 2005 | -94.73 Million DKK | -78.69% |
| 2004 | -53.01 Million DKK | -135.21% |
| 2003 | 150.56 Million DKK | 114.72% |
| 2002 | 70.12 Million DKK | 176.15% |
| 2001 | -92.08 Million DKK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 261.12 Million DKK | 328.16% |
| 2024 Q1 | -114.45 Million DKK | -112.7% |
| 2023 Q2 | 538.07 Million DKK | 42.97% |
| 2023 FY | 1.47 Billion DKK | 524.66% |
| 2023 Q3 | -340.64 Million DKK | -163.31% |
| 2023 Q4 | 901.39 Million DKK | 364.61% |
| 2023 Q1 | 376.36 Million DKK | 151.54% |
| 2022 FY | -347.38 Million DKK | 25.26% |
| 2022 Q3 | 12.1 Million DKK | 105.11% |
| 2022 Q1 | -271.94 Million DKK | -166.01% |
| 2022 Q2 | -237.17 Million DKK | 12.79% |
| 2022 Q4 | 149.62 Million DKK | 1135.74% |
| 2021 FY | -464.77 Million DKK | -267.47% |
| 2021 Q1 | -130.84 Million DKK | 65.08% |
| 2021 Q2 | -150.25 Million DKK | -14.84% |
| 2021 Q3 | -81.44 Million DKK | 45.8% |
| 2021 Q4 | -102.23 Million DKK | -25.53% |
| 2020 Q2 | 111.27 Million DKK | -78.38% |
| 2020 Q3 | 26.34 Million DKK | -76.32% |
| 2020 Q4 | -374.68 Million DKK | -1521.99% |
| 2020 FY | 277.52 Million DKK | 180.03% |
| 2020 Q1 | 514.57 Million DKK | 1221.35% |
| 2019 Q1 | -99.62 Million DKK | 1.74% |
| 2019 Q2 | -102.08 Million DKK | -2.47% |
| 2019 Q3 | -99.18 Million DKK | 2.84% |
| 2019 FY | -346.77 Million DKK | 4.19% |
| 2019 Q4 | -45.88 Million DKK | 53.73% |
| 2018 Q2 | -109.81 Million DKK | 39.81% |
| 2018 FY | -361.92 Million DKK | -299.58% |
| 2018 Q1 | -182.44 Million DKK | 1.15% |
| 2018 Q4 | -101.38 Million DKK | -419.64% |
| 2018 Q3 | 31.71 Million DKK | 128.88% |
| 2017 FY | 181.34 Million DKK | 492.62% |
| 2017 Q3 | 325.67 Million DKK | 603.5% |
| 2017 Q2 | 46.29 Million DKK | 865.05% |
| 2017 Q1 | -6.05 Million DKK | -106.93% |
| 2017 Q4 | -184.57 Million DKK | -156.67% |
| 2016 Q4 | 87.31 Million DKK | -10.74% |
| 2016 Q2 | -25.78 Million DKK | 79.98% |
| 2016 Q1 | -128.75 Million DKK | -5661.68% |
| 2016 FY | 30.6 Million DKK | -48.51% |
| 2016 Q3 | 97.81 Million DKK | 479.4% |
| 2015 FY | 59.42 Million DKK | 129.09% |
| 2015 Q4 | 2.31 Million DKK | 104.66% |
| 2015 Q3 | -49.62 Million DKK | -180.95% |
| 2015 Q2 | 61.3 Million DKK | 35.02% |
| 2015 Q1 | 45.4 Million DKK | -53.65% |
| 2014 Q2 | -54.9 Million DKK | -4675.0% |
| 2014 Q4 | 97.94 Million DKK | 635.19% |
| 2014 Q3 | -18.3 Million DKK | 66.67% |
| 2014 FY | 25.94 Million DKK | 155.51% |
| 2014 Q1 | 1.2 Million DKK | 104.47% |
| 2013 Q3 | 19.2 Million DKK | 462.26% |
| 2013 Q4 | -26.82 Million DKK | -239.73% |
| 2013 FY | -46.72 Million DKK | 80.53% |
| 2013 Q1 | -33.8 Million DKK | 45.57% |
| 2013 Q2 | -5.3 Million DKK | 84.32% |
| 2012 FY | -240 Million DKK | 26.0% |
| 2012 Q4 | -62.1 Million DKK | -413.64% |
| 2012 Q3 | 19.8 Million DKK | 111.76% |
| 2012 Q2 | -168.4 Million DKK | -474.74% |
| 2012 Q1 | -29.3 Million DKK | 38.5% |
| 2011 Q4 | -47.63 Million DKK | 5.1% |
| 2011 FY | -324.33 Million DKK | 43.79% |
| 2011 Q1 | -108.8 Million DKK | 58.97% |
| 2011 Q2 | -117.7 Million DKK | -8.18% |
| 2011 Q3 | -50.2 Million DKK | 57.35% |
| 2010 Q2 | -55.4 Million DKK | 40.37% |
| 2010 Q1 | -92.9 Million DKK | 49.48% |
| 2010 Q4 | -265.16 Million DKK | -61.98% |
| 2010 FY | -576.96 Million DKK | -45.7% |
| 2010 Q3 | -163.7 Million DKK | -195.49% |
| 2009 Q2 | -82.8 Million DKK | -24.89% |
| 2009 Q1 | -66.3 Million DKK | 0.0% |
| 2009 FY | -395.98 Million DKK | -83.12% |
| 2009 Q4 | -183.88 Million DKK | -191.89% |
| 2009 Q3 | -63 Million DKK | 23.91% |
| 2008 FY | -216.24 Million DKK | -240.52% |
| 2007 FY | -63.5 Million DKK | 60.54% |
| 2006 FY | -160.93 Million DKK | -69.89% |
| 2005 FY | -94.73 Million DKK | -78.69% |
| 2004 FY | -53.01 Million DKK | -135.21% |
| 2003 FY | 150.56 Million DKK | 114.72% |
| 2002 FY | 70.12 Million DKK | 176.15% |
| 2001 FY | -92.08 Million DKK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ALK-Abelló A/S | 486 Million DKK | -203.537% |
| Genmab A/S | 4.35 Billion DKK | 66.103% |
| Gubra A/S | -44.52 Million DKK | 3413.245% |
| Novo Nordisk A/S | 83.68 Billion DKK | 98.237% |
| Orphazyme A/S | -26.04 Million DKK | 5763.348% |
| Pharma Equity Group A/S | -24.6 Million DKK | 6094.51% |
| Zealand Pharma A/S | -703.73 Million DKK | 309.622% |